Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
Recruiting · Phase 1 · NCT06598800
Conditions: Advanced Solid Tumor
At a glance
- Research payments reported, 2025
- $363,653
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 153
About the trial
- Sponsor
- BeOne Medicines
- Tested
- Drug: BG-T187 (drug), Other Therapeutic Agents (drug)
- Dates
- Started 2024-10-18; completion 2028-09-30
- Results posted
- Not yet
This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.
From ClinicalTrials.gov, last updated 2026-09-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $363,653 in research payments for this study in 2025 (33 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Martin E. Gutierrez, MD Medical Oncology · Hackensack, NJ
- David S. Hong, M.D. Medical Oncology · Houston, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Next Virginia, LLC $211,089
- Ut MD Anderson Cancer Center $81,803
- Hackensack University Medical Center, NJ $70,762
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.